[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Marea Therapeutics\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":93},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100642607","phase-2-a-study-to-evaluate-mar002-for-acromegaly-100642607",false,"NCT07641179","A Study to Evaluate MAR002 for Acromegaly","A Phase 2, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MAR002 in Participants With Acromegaly (TROUGH-2)","Inclusion Criteria:\n\n1. Willing to provide written informed consent and comply with study procedures as specified in this protocol and comply with study treatment.\n2. Age 18 to 75 years (inclusive) at screening with active acromegaly confirmed by an endocrinologist specialized in the care of pituitary patients. At a minimum, there must be documentation of a pituitary tumor (e.g., imaging evidence of a pituitary tumor by magnetic resonance imaging \\[MRI\\]\u002Fcomputerized tomography \\[CT\\] or histopathologic evidence of pituitary adenoma following pituitary surgery) and an elevated IGF-1 in the past.\n3. Participants receiving acromegaly medical therapy at screening (i.e., Group 2 and Group 3) may be enrolled if the regimen is considered stable by the Investigator and must agree to wash out acromegaly treatment, if applicable per protocol.\n4. Average serum IGF-1 level of ≥ 1.3 × ULN defined as the mean of 2 measurements obtained ≥ 1 week apart during Screening.\n5. Participants with hypothyroidism and adrenal insufficiency should have these hormone axes adequately replaced as judged by the Investigator.\n6. Weight ≥ 50 kg at screening.\n\nExclusion Criteria:\n\n1. History of hypersensitivity to monoclonal antibodies.\n2. Participation in any other investigational drug study and received the last dose of investigational drug within 60 days or 5 half-lives (whichever is longer) of SV1.\n3. History of severe allergic or anaphylactic reactions.\n4. History of malignancy within 5 years prior to screening other than successfully treated basal or squamous cell carcinoma or localized cervical carcinoma. Any carcinoma in situ is allowed if appropriately treated within 2 years prior to screening. Subjects with a history of malignancy ≥ 5 years prior to screening should be considered cured of their oncological disease.\n5. Pituitary surgery in the past 6 months prior to screening or any prior use of pituitary radiation therapy.\n6. Pituitary adenoma with concern for mass effect on the optic chiasm or other critical structures within the study period as per judgment of the Investigator.\n7. Poorly controlled diabetes mellitus, defined as having a hemoglobin A1c (HbA1c) ≥ 9.0%.\n8. Severe renal insufficiency (estimated glomerular filtration rate \\[eGFR by Chronic Kidney Disease Epidemiology Collaboration\\] \\\u003C 30 mL\u002Fmin\u002F1.73 m2) or significant liver disease (including cirrhosis) prior to randomization.\n9. History or evidence of any of the following within the previous 12 months: myocardial infarction, cardiac surgery revascularization (coronary artery bypass grafting or percutaneous transluminal coronary angioplasty), hospitalization for heart failure, or stroke or transient ischemic attack.","ALL","18 Years","75 Years",{"count":20,"type":21},72,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in participants with acromegaly",[27],"Acromegaly",[29,30,31],"Marea","MAR002","MAR-202","NOT_YET_RECRUITING","2026-06-10",{"date":35,"type":36},"2026-06-12","ACTUAL",{"date":38,"type":21},"2026-07",{"date":40,"type":21},"2027-12",{"name":42,"class":43},"Marea Therapeutics","INDUSTRY",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":52,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":67,"locationsCount":68},"100607947","phase-1-study-of-mar002-in-healthy-men-100607947","NCT07195175","Study of MAR002 in Healthy Men","First in Human, Randomized, Blinded, Placebo-Controlled Single Ascending Dose and Multiple Dose Study of MAR002 in Healthy Men","Inclusion Criteria:\n\n1. Willingness to provide written informed consent\n2. Age 18 to 40\n3. Weight 55 to 95 kg\n4. Body mass index (BMI) 18 to 30 kg\u002Fm2\n5. Healthy men\n\nExclusion Criteria:\n\n1. History of hypersensitivity to monoclonal antibodies or study drug\n2. Participation in any other investigational drug study\n3. History of cancer\n4. Recent acute illness\n5. Positive test for HIV, hepatitis B\u002FC\n6. History of substance abuse or nicotine use\n7. Recent blood donation\n8. History of pituitary disorder\n9. Any condition that prevents the participant from complying with study procedures",true,"MALE","40 Years",{"count":55,"type":21},45,[57],"PHASE1","Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in healthy men",[27],"RECRUITING","2026-01-08",{"date":63,"type":36},"2026-01-12",{"date":65,"type":36},"2025-08-11",{"date":38,"type":21},{"name":42,"class":43},1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":68},"100608265","phase-2-a-mechanistic-study-of-mar001-in-adults-with-elevated-triglycerides-and-remnant-cholesterol-100608265","NCT07199309","A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol","Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of MAR001 on Postprandial Lipids in Patients With Elevated Triglycerides and Remnant Cholesterol","Inclusion Criteria:\n\n* Willingness to provide informed consent and comply with the intervention and all study assessments\n* Two fasting TG collected at two separate, consecutive visits at least 7 days apart during the Screening period\n* HbA1c ≥ 5.7% and ≤ 8.5%\n* Stable diet for a minimum of 3 months prior to screening and with no plans to change diet through duration of study\n* Stable drug regimen (appropriate if relevant) prior to screening visit and no planned changes during screening or trial participation\n\nExclusion Criteria:\n\n* Acute or chronic liver disease\n* Diabetes medications (other than metformin)\n* History of type 1 diabetes mellitus or history of diabetic ketoacidosis\n* Newly diagnosed T2DM\n* Participants with known active hepatitis A, B, or C\n* Participants who are known to have uncontrolled human immunodeficiency virus (HIV) infection\n* Uncontrolled hypothyroidism\n* Any condition that prevents the participant from complying with study procedures",{"count":77,"type":21},30,[24],"The primary objective of the study is to determine the effect of MAR001 as compared to placebo on levels of the triglycerides (TG) in the postprandial state in adults with elevated TG.",[81],"Hypertriglyceridemia",[83,84,81],"Remnant Cholesterol","MAR001","2025-11-04",{"date":87,"type":36},"2025-11-06",{"date":89,"type":36},"2025-09-26",{"date":91,"type":21},"2026-11",{"name":42,"class":43},""]